By: Stephanie Renno, DSW, LCSW, Deputy Chief Clinical Officer at A-G Associates
Every June, Post Traumatic Stress Disorder (PTSD) Awareness Month means the Military and Veteran space is saturated with information about the diagnosis. This year, I thought my contribution could take a different direction, with the goal of being real and the hope of initiating candid conversation. This post is my take on the social media trend where professionals say the quiet parts out loud— the perspectives they typically soften or sidestep to avoid controversy. In honor of PTSD Awareness Month, I’m adding my voice to that conversation.
These aren't fringe opinions. Most PTSD researchers and evidence-based clinicians would likely agree with at least some of what follows. But PTSD, particularly PTSD in Veterans, is an inherently political topic, and there's real pressure to stay in safe, uncontroversial territory. I hope to open a constructive dialogue rather than shut it down.
What connects the three points below is a single throughline: the field has a habit of prioritizing comfort over clarity — softening language to avoid offense, tolerating treatment variability to avoid conflict, and letting enthusiasm outpace accountability to avoid slowing momentum.
Each of those instincts is understandable.
None of them serve patients.
1. Dropping the "D" from PTSD doesn't reduce stigma; it minimizes the severity of a real neurological disorder.
There is a movement to shift calling "PTSD" to "PTS" to reduce stigma. While I deeply respect the right of individuals to define and label their own experience, I disagree with healthcare providers making this call.
When it comes to diagnosis, there's an important distinction worth making: posttraumatic stress describes the symptoms that follow a traumatic event. Nearly everyone experiences some version of this reaction after trauma, and for most people, those symptoms resolve within weeks, most often outside of a behavioral health setting.
Posttraumatic Stress Disorder is something different. It is a persistent, clinically significant condition that disrupts functioning and fundamentally changes how the brain processes the world.
Precise terminology matters in medicine because different problems require different treatments. What works for posttraumatic stress is not the same as what treats PTSD. But the stakes go beyond clinical accuracy, refusing to call something a disorder sends an implicit message that the label itself is shameful, rather than treating it like any other medical condition we'd diagnose and treat without apology.
I understand the concern that the word ‘disorder’ feels like it reduces Veterans to a diagnosis, but the answer isn’t to soften the name; it's to change how we talk about what the diagnosis means and to raise awareness that PTSD is treatable. We can’t change what happened, but we can reduce or eliminate the problems the resulting symptoms are causing.
We wouldn't rename cancer to spare people's feelings. The impulse to soften "PTSD" suggests that people living with this disorder can't handle an accurate description of their own condition. That's not destigmatization. That's condescension.
2. Systems should regulate how PTSD care is delivered.
Healthcare systems, payers, and clinical supervisors have a responsibility to regulate PTSD treatment, and most aren't doing enough of it.
Therapists bring a lot of themselves into their work, and yet treatment should not be based on that provider’s feelings.
To stay with the cancer analogy: an oncologist cannot select treatment protocols based on personal preference. Deviating from evidence-based clinical practice guidelines requires rigorous documentation and justification, and providers who abandon first-line treatments without cause risk losing their license. Behavioral health doesn't hold itself to the same standard, and yet it should.
Even when a suboptimal treatment causes no direct harm, harm still occurs; time is lost, money is spent, and the patient is left with the impression that nothing works for them. That sense of defeat can be devastating and can actively discourage people from seeking effective care. PTSD is treatable, but individuals can’t get the treatment if it’s offered at clinician discretion.
3. Psychedelic-assisted therapy needs guardrails now, before the momentum outpaces the safeguards.
The early evidence on psychedelics for PTSD is genuinely exciting. But the promise of these treatments will only be realized if they are delivered safely, with clear, consensus-based guidance for practitioners; guidance that defines who should administer them, under what conditions, and what is and isn't acceptable practice.
Continuing the cancer analogy, chemotherapy offers a useful model: a powerful treatment with documented efficacy, administered within a structured framework of safety protocols designed to protect highly vulnerable patients.
Psychedelic-assisted therapy needs the same infrastructure. The vulnerability that makes these treatments potentially transformative is the same vulnerability that creates serious risk when oversight is absent. Getting this right isn't a barrier to progress— it's a prerequisite for it.
Conclusion
PTSD is too serious, and the people living with it too deserving of good care, for the field to keep avoiding hard conversations. Precision in language, accountability in systems, and rigor in emerging treatments aren't obstacles to progress, they are the foundation of it. I'd rather have a difficult dialogue now than a preventable failure later.
For a Veteran's perspective on community, growth, and owning the conversation, see Chris Gonzalez's companion piece.
Learn More
A-G Associates is at the forefront, driving impactful results in behavioral health, military wellbeing, and systems transformation. Learn more about our results and get in touch to partner in driving change and advancing the field.